rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IMNN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Imunon (IMNN) Q3 2026 Earnings Call Transcript

      Detailed price information for Arm Holdings Plc ADR (ARM-Q) from The Globe and Mail including charting and trades.

      Nov 12The Globe and MailIMNN
      Imunon Q3 2026 Earnings Call Transcript
      Nov 12BenzingaIMNN
      IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update
      Nov 12Yahoo FinanceIMNN
      IMUNON presents translational data from ovarian cancer trial
      Nov 6Investing.comIMNN
      IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer
      Nov 6Yahoo FinanceIMNN
      IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026

      LAWRENCEVILLE, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference call at 11:00 a.m. EST on Thursday, November 12, 2026 to discuss financial results for the quarter ended September 30, 2026 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy, including progress in advancing P

      Nov 2Yahoo FinanceIMNN
      Imunon sells ThermoDox rights to VoxelDox Therapeutics
      Oct 21Investing.comIMNN
      IMUNON Announces Strategic Sale of ThermoDox®
      Oct 21Yahoo FinanceIMNN
      IMUNON to Participate in Upcoming Investor Conferences
      Oct 8Yahoo FinanceIMNN
      IMNN: R&D Day Highlights IMNN-001 Data in Frontline Ovarian Cancer

      By David Bautz, PhD NASDAQ: IMNN READ THE FULL IMNN RESEARCH REPORT Business Update R&D Day Highlights IMNN-001 in Advanced Ovarian Cancer On September 23, 2026, Imunon, Inc. (NASDAQ: IMNN) held an R&D Day to discuss the IMNN-001 program, which included a discussion on the use of localized IL-12 in cancer therapy, translational data that showed IMNN-001 is preferentially taken up by

      Oct 1Yahoo FinanceIMNN
      Imunon Introduces Series B Preferred to Restructure Debt
      Sep 30The Globe and MailIMNN
      Imunon exchanges $1.2M debt for preferred stock
      Sep 29Investing.comIMNN
      IMUNON Converts $1.2 Million of Debt-to-Equity
      Sep 29Yahoo FinanceIMNN
      Imunon, Inc. (IMNN) Shareholder/Analyst Call - Slideshow (NASDAQ:IMNN) 2026-09-24

      2026-09-24. The following slide deck was published by Imunon, Inc.

      Sep 24Seeking AlphaIMNN
      Imunon presents Phase 2 ovarian cancer survival data at R&D day
      Sep 24Investing.comIMNN
      IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

      2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory readout in OVATION 3 Testimonial conversation with an OVATION 1 participant now 10 years from diagnosis LAWRENCEVILLE, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today is presenting an update on its

      Sep 24Yahoo FinanceIMNN
      IMUNON’s ovarian cancer study continues after safety review
      Sep 22Investing.comIMNN
      IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

      Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date No cytokine release syndrome, systemic toxicities or serious immune-related adverse events observed to date, reinforcing IMNN-001's differentiated safety profile as an IL-12-based immunotherapy MRD study has now demonstrated the safety and tolerability of IMNN-001 both in combination with bevacizumab and in the maintenance setting Recommenda

      Sep 22Yahoo FinanceIMNN
      IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

      Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens IMUNON retains ownership of its background intellectual property with an opportunity to expand its IP through this collaboration LAWRENCEVILLE, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced it has entered into a Cooperative Research and Development

      Sep 10Yahoo FinanceIMNN
      Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy
      Sep 9Investing.comIMNN
      IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

      Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced the agenda and speaker lineup for its upcoming R&D Day highlighting IMNN-001, the Company’s investigational IL-12 immunotherapy. The event will be held at the Sofitel

      Sep 9Yahoo FinanceIMNN
      Imunon to host R&D day on phase 3 ovarian cancer trial
      Aug 26Investing.comIMNN
      Imunon to host R&D day on Sept. 23 for ovarian cancer therapy
      Aug 26Investing.comIMNN
      IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001
      Aug 26BarchartIMNN

      This is the newest page. Registered accounts read further back.